I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Heart failure is a major public health concern and the most common cause for hospitalization.\[[@ref1]\] The standard treatment of heart failure fails to improve cardiac systolic function in more than a third of patients with Stage C or D heart failure.\[[@ref2]\] Increasing evidence suggests that heart failure is preventable and treatable in the early stage.\[[@ref3]\] Thus, it is important to develop an earlier and more sensitive evaluation index of cardiac systolic function during the early stage of heart failure.

Excitation--contraction (E-C) coupling is an important indicator of cardiomyocyte contractile function.\[[@ref4]\] Our previous study suggests that the efficiency between a single L-type channel and its controlled-Ca^2+^-release channels decrease before the appearance of cardiac systolic and cardiomyocyte contractile dysfunction at the early stage of heart failure in animal models.\[[@ref5]\] The basic characteristics of E-C coupling are a series of stereotyped events that are responsible for the rapid mechanical contraction response of muscle fibers to an initial electrical event at the surface.\[[@ref6][@ref7][@ref8]\] Thus, we speculated whether the electromechanical coupling of the cardiac muscle is a more sensitive indicator in the evaluation of cardiac systolic function compared with left ventricular ejection fraction (LVEF) in the early stage of heart failure patients.

Echocardiogram (echo) and electrocardiogram (ECG) are widely used to evaluate the structural changes and mechanical activity\[[@ref9]\] and the electrical activity of the heart,\[[@ref10]\] respectively. However, no specific medical test can detect the cardiac electromechanical coupling efficiency. The Q wave on ECG represents the beginning of ventricular electrical activity and the S wave on tissue Doppler imaging (TDI) represents the beginning of ventricular systolic activity. The time course from Q wave to S wave reflects the electromechanical coupling efficiency of left ventricular. Thus, we aimed to measure ventricular electromechanical coupling time course by combining TDI measurement of echo and ECG measurement and study its role in the evaluation of cardiac systolic function.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The procedure was approved by the Ethics Committee of Peking University Third Hospital (Approval No. IRB00006761-2016125) and in accordance with the *Declaration of Helsinki* 1975, as revised in 2000. All individuals provided written informed consent before taking part in this study.

Study population {#sec2-2}
----------------

We consecutively evaluated 26 patients with Stage B heart failure (SBHF) and 31 age- and sex-matched healthy controls (CONs). All CONs were recruited before the initiation of the study. CONs did not have a history of hypertension, diabetes, cardiovascular disease, or cerebrovascular disease. SBHF patients were diagnosed with hypertensive myocardial hypertrophy by echo (interventricular septum \[IVS\] thickness ≥11 mm or left ventricular posterior wall \[LVPW;d\] ≥11 mm or left ventricular mass index \[LVMI\] ≥115 g/cm^2^). Volunteers with inflammatory disease, with allergy, who are taking drugs that affect the immune or endocrine system, and/or with alcoholism were excluded from the study.

Echocardiographic measurement {#sec2-3}
-----------------------------

Echo was performed as described previously.\[[@ref11]\] A Vivid GE 7 color ultrasonic diagnostic instrument (GE, Fairfield, CT, USA) with a probe of 1.7--3.4 MHz frequency was used to measure the IVS, LVPW;d, Left ventricular end-diastolic dimension (LVEDD), and Left ventricular end-systolic dimension (LVESD) in M-mode echo. Relative wall thickness (RWT) was calculated using the following formula: RWT = (2 × LVPW;d)/LVEDD. The left ventricular mass (LVM) and LVMI were calculated according to the Devereux formula: LVM (g) = 0.8 × 1.04 × (\[IVS + LVPW;d + LVEDD\]^3^ − LVEDD^3^) + 0.6, LVMI (g/m^2^) = LVM/BSA, respectively, the body surface area (BSA) was calculated as follows: BSA = 0.0061 × height (cm) + 0.0128 × weight (kg) − 0.1529. LVEF was calculated by the Teicholz method. The values of three consecutive cardiac cycles were measured.

Electromechanical coupling time measurement {#sec2-4}
-------------------------------------------

ECG was performed as described previously.\[[@ref12]\] The TDI echo combined with ECG was used to evaluate the four time courses (Qsb, Qst, Rsb, and Rst) in all six walls of the left ventricle, namely the lateral wall (Lat), anterior wall (Ant), inferior wall (Inf), posterior wall (PW), posterior ventricular septum (Pivs), and anterior ventricular septum (Aivs). The time measurement module of Vivid GE 7 color ultrasonic diagnostic instrument was used to detect the time course of Qsb, Qst, Rsb, and Rst. Qsb time course is from the onset of Q wave on ECG to beginning of S wave on TDI. Qst time course is from the onset of Q wave on ECG to top of S wave on TDI. Rsb time course is from the top of R wave on ECG to beginning of S wave on TDI. Rst time course is from the top of R wave on ECG to top of S wave on TDI.

Statistical analysis {#sec2-5}
--------------------

All statistical analyses were conducted using SPSS software version 19.0 (SPSS Inc., Chicago, IL, USA). The data are expressed as mean ± standard deviation (SD). The results were compared using Student\'s *t*-test. A value of *P* \< 0.05 was considered statistically significant. Sensitivity and specificity analyses were conducted using MedCalc version 14 software (MedCalc Inc., Ostend, Belgium), and a *P* \< 0.05 was considered statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Clinical characteristics of Stage B heart failure patients and healthy controls {#sec2-6}
-------------------------------------------------------------------------------

The clinical characteristics of SBHF patients and CONs are given in [Table 1](#T1){ref-type="table"}. There were no significant differences in age, body mass index (BMI), and heart rate (HR) between SBHF and CON groups (age: 46.00 ± 11.56 vs. 42.65 ± 13.61, *t* = −1.006, *P* = 0.319; BMI: 25.00 ± 3.12 vs. 23.75 ± 3.01, *t* = −1.541, *P* = 0.129, HR: 74.73 ± 13.75 vs. 72.35 ± 9.58 *t* = −0.766, *P* \< 0.001). The systolic blood pressure (SBP) and diastolic blood pressure (DBP) in SBHF patients were significantly higher than those of CONs (SBP: 156.23 ± 25.14 vs. 118.77 ± 8.88, *t* = −7.299, *P* \< 0.001;DBP: 93.04 ± 15.76 vs. 71.58 ± 9.07, *t* = −6.426, *P* \< 0.001) \[[Table 1](#T1){ref-type="table"}\].

###### 

Comparison of the general characteristics of study population

  Items            CONs (*n* = 31)   SBHF patients (*n* = 26)   *t*      *P*
  ---------------- ----------------- -------------------------- -------- ---------
  Age (year)       42.65 ± 13.61     46.00 ± 11.56              −1.006   0.319
  BMI (kg/m^2^)    23.75 ± 3.01      25.00 ± 3.12               −1.541   0.129
  HR (beats/min)   72.35 ± 9.58      74.73 ± 13.75              −0.766   0.447
  SBP (mmHg)       118.77 ± 8.88     156.23 ± 25.14             −7.229   \<0.001
  DBP (mmHg)       71.58 ± 9.07      93.04 ± 15.76              −6.426   \<0.001

Data are expressed as mean ± SD. BMI: Body mass index; HR: Heart rate; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; SD: Standard deviation; CONs: Healthy controls; SBHF: Stage B heart failure.

Standard echocardiographic parameters of Stage B heart failure patients and healthy controls {#sec2-7}
--------------------------------------------------------------------------------------------

Echocardiographic data showed that the indexes reflecting myocardial hypertrophy in SBHF patients were much higher than those in CONs. As shown in [Table 2](#T2){ref-type="table"}, the thickness of IVS and LVPW;d significantly increased in SBHF patients compared with those of CONS (IVS: 12.14 ± 1.17 vs. 8.09 ± 1.06, *t* = −13.702, *P* \< 0.001; LVPW;d: 11.78 ± 0.94 vs. 8.13 ± 0.89, *t* = −15.017, *P* \< 0.001). RWT and LVMI were significantly higher in SBHF patients than in CONs (RWT: 0.45 ± 0.04 vs. 0.34 ± 0.04, *t* = −9.974, *P* \< 0.001; LVMI: 134.07 ± 30.37 vs. 75.96 ± 14.24, *t* = −8.964, *P* \< 0.001). The average LVEDD and LVESD in SBHF patients were larger than those in CONs (LVEDD: 52.54 ± 4.71 vs. 48.1 ± 3.38, *t* = −4.136, *P* \< 0.001, LVESD: 33.52 ± 5.28 vs. 29.84 ± 2.71, *t* = −3.222, *P* = 0.003). SBHF patients had significantly lower than those in CONs for the E/A and E/Em ratios (E/A: 0.98 ± 0.49 vs. 1.34 ± 0.40, *t* = 3.053, *P* = 0.003, E/Em: 10.28 ± 3.80 vs. 5.72 ± 0.65, *t* = −5.687, *P* \< 0.001). However, there was no significant difference in LVEF between SBHF patients and CONs (64.23 ± 8.91 vs. 64.52 ± 5.90, *t* = 0.145, *P* = 0.886).

###### 

Comparison of M-mode echocardiographic measurement parameters

  Items           CONs (*n* = 31)   SBHF patients (*n* = 26)   *t*       *P*
  --------------- ----------------- -------------------------- --------- ---------
  IVS (mm)        8.09 ± 1.06       12.14 ± 1.17               −13.702   \<0.001
  LVPW;d (mm)     8.13 ± 0.89       11.78 ± 0.94               −15.017   \<0.001
  LVEDD (ml)      48.10 ± 3.38      52.54 ± 4.71               −4.136    \<0.001
  LVESD (ml)      29.84 ± 2.71      33.52 ± 5.28               −3.222    0.003
  RWT             0.34 ± 0.04       0.45 ± 0.04                −9.974    \<0.001
  LVMI (g/m^2^)   75.96 ± 14.24     134.07 ± 30.37             −8.964    \<0.001
  LVEF (%)        64.52 ± 5.90      64.23 ± 8.91               0.145     0.886
  E/A             1.34 ± 0.40       0.98 ± 0.49                3.053     0.003
  E/Em            5.72 ± 1.65       10.28 ± 3.80               −5.687    \<0.001

Data are expressed as mean ± SD. IVS: Inter-ventricular septum; LVPW;d: Left ventricular posterior wall; LVEDD: Left ventricular end-diastolic dimension; LVESD: Left ventricular end-systolic dimension; RWT: Relative wall thickness; LVMI: Left ventricular mass index; LVEF: Left ventricular ejection fraction; SD: Standard deviation; CONs: Healthy controls; SBHF: Stage B heart failure; ECG: Electrocardiography; TDI: Tissue Doppler imaging.

Electromechanical coupling time parameters of Stage B heart failure patients and healthy controls {#sec2-8}
-------------------------------------------------------------------------------------------------

Four cardiac electromechanical coupling time courses in Lat of the left ventricle (Lat-Rst, Lat-Rsb, Lat-Qst, and Lat-Qsb) of CONs \[[Figure 1a](#F1){ref-type="fig"}\] and SBHF patients \[[Figure 1b](#F1){ref-type="fig"}\] were evaluated by TDI echo combined with ECG. The measurement showed that the four electromechanical coupling parameters in SBHF patients were all longer than those in CONs \[Lat-Rst: 122.37 ± 36.66 vs. 93.25 ± 16.72, *t* = −3.696, *P* = 0.001, [Figure 1c](#F1){ref-type="fig"}; Lat-Rsb: 82.43 ± 33.66 vs. 48.30 ± 15.18, *t* = −4.779, *P* \< 0.001, [Figure 1d](#F1){ref-type="fig"}; Lat-Qst: 165.42 ± 60.93 vs. 129.04 ± 16.97, *t* = −2.951, *P* = 0.006, [Figure 1e](#F1){ref-type="fig"}; Lat-Qsb: 119.19 ± 35.68 ms vs. 80.30 ± 14.81 ms, *t* = −5.196, *P* \< 0.001, [Figure 1f](#F1){ref-type="fig"}, respectively\] \[[Table 3](#T3){ref-type="table"}\]. In addition, the sensitivity and specificity analyses showed that the Lat-Rst, Lat-Rsb, and Lat-Qsb were significantly better than LVEF \[Rst: *P* = 0.032, [Figure 2a](#F2){ref-type="fig"}; Rsb: *P* = 0.003, [Figure 2b](#F2){ref-type="fig"}; and Qsb: *P* = 0.004, [Figure 2d](#F2){ref-type="fig"}\]. While, the sensitivity and specificity of Lat-Qst was not significantly different from the LVEF \[*P* = 0.126, [Figure 2c](#F2){ref-type="fig"}\] similar trends were also observed in the Pivs, Ant, Inf, PW, and Aivs \[[Table 3](#T3){ref-type="table"}\].

![Cardiac electromechanical coupling time in SBHF patients and CONs. Representative images of TDI combined with ECG to measure the electromechanical coupling time in the lateral wall of the left ventricle (Lat) of CON subjects (a) and SBHF patients (b). Statistical data of Lat-Rst (c), Lat-Rsb (d), Lat-Qst (e), and Lat-Qsb (f) in SBHF patients group and CON group. Data are mean ± SD. \**P* \< 0.05 versus CON. CONs: Healthy controls; TDI: Tissue Doppler imaging; ECG: Electrocardiography; SBHF: Stage B heart failure; Rst: From the top of R wave on ECG to the top of S wave on TDI; Rsb: From the top of R wave on ECG to the beginning of S wave on TDI; Qst: From the onset of Q wave on ECG to the top of S wave on TDI; Qsb: From the onset of Q wave on ECG to the beginning of S wave on TDI; SD: Standard deviation.](CMJ-131-1834-g001){#F1}

###### 

Comparison of cardiac E-C coupling measurement parameters of study population

  Items           CONs (*n* = 31)   SBHF patients (*n* = 26)   *t*      *P*
  --------------- ----------------- -------------------------- -------- ---------
  Lat-Qsb (ms)    80.30 ± 14.81     119.19 ± 35.68             −5.196   \<0.001
  Lat-Qst (ms)    129.04 ± 16.97    165.42 ± 60.93             −2.951   0.006
  Lat-Rsb (ms)    48.30 ± 15.18     82.43 ± 33.66              −4.779   \<0.001
  Lat-Rst (ms)    93.25 ± 16.72     122.37 ± 36.66             −3.696   0.001
  Pivs-Qsb (ms)   80.32 ± 17.35     109.11 ± 28.35             −4.516   \<0.001
  Pivs-Qst (ms)   127.80 ± 20.45    154.07 ± 38.45             −3.131   0.003
  Pivs-Rsb (ms)   48.87 ± 13.70     73.88 ± 22.45              −4.960   \<0.001
  Pivs-Rst (ms)   74.20 ± 11.57     92.96 ± 34.32              −2.663   0.012
  Ant-Qsb (ms)    79.37 ± 12.47     114.89 ± 37.51             −4.619   \<0.001
  Ant-Qst (ms)    127.00 ± 16.13    162.46 ± 57.69             −3.037   0.005
  Ant-Rsb (ms)    47.84 ± 12.94     79.86 ± 31.27              −4.882   \<0.001
  Ant-Rst (ms)    92.19 ± 16.13     125.29 ± 51.84             −3.132   0.004
  Inf-Qsb (ms)    82.47 ± 17.81     106.22 ± 23.63             −4.323   \<0.001
  Inf-Qst (ms)    127.42 ± 22.58    153.41 ± 40.29             −2.926   0.006
  Inf-Rsb (ms)    50.13 ± 16.60     74.23 ± 19.23              −5.078   \<0.001
  Inf-Rst (ms)    97.85 ± 22.51     119.5 ± 33.3               −2.914   0.005
  PW-Qsb (ms)     81.89 ± 17.35     112.1 ± 30.53              −4.476   \<0.001
  PW-Qst (ms)     130.30 ± 17.76    160.96 ± 54.28             −2.759   0.010
  PW-Rsb (ms)     49.28 ± 14.77     78.47 ± 27.37              −4.873   \<0.001
  PW-Rst (ms)     95.14 ± 17.73     128.76 ± 44.65             −3.608   0.001
  Aivs-Qsb (ms)   83.33 ± 17.45     103.6 ± 25.1               −3.476   0.001
  Aivs-Qst (ms)   125.10 ± 20.17    153.35 ± 36.64             −3.677   0.001
  Aivs-Rsb (ms)   51.13 ± 13.84     70.78 ± 21.2               −4.056   \<0.001
  Aivs-Rst (ms)   93.34 ± 17.84     117.03 ± 32.22             −3.486   0.001

Data are expressed as mean ± SD. Lat: Lateral wall of left ventricle; Pivs: Posterior ventricular septum of left ventricle; Ant: Anterior wall of left ventricle; Inf: Inferior wall of left ventricle; PW: Posterior wall of left ventricle; Aivs: Anterior ventricular septum of left ventricle; Qsb: From the onset of Q wave on ECG to the beginning of S wave on TDI; Qst: From the onset of Q wave on ECG to the top of S wave on TDI; Rsb: From the top of R wave on ECG to the beginning of S wave on TDI; Rst: From the top of R wave on ECG to the top of S wave on TDI; SD: Standard deviation; CONs: Healthy controls; SBHF: Stage B heart failure; ECG: Electrocardiography; TDI: Tissue Doppler imaging; E-C: Excitation-contraction.

![Comparison of sensitivity and specificity between Lat-Rst and LVEF, *P* = 0.032 (a), between Lat-Rsb and LVEF, *P* = 0.003 (b), between Lat-Qst and LVEF, *P* = 0.126 (c), and between Lat-Qsb and LVEF, *P* = 0.004 (d). LVEF: Left ventricular ejection fraction; Rst: From the top of R wave on ECG to the top of S wave on TDI; Rsb: From the top of R wave on ECG to the beginning of S wave on TDI; Qst: From the onset of Q wave on ECG to the top of S wave on TDI; Qsb: From the onset of Q wave on ECG to the beginning of S wave on TDI.](CMJ-131-1834-g002){#F2}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

The results of our research suggested that the electromechanical coupling time is more sensitive and specific than LVEF in evaluating cardiac systolic function \[Figure [2a](#F2){ref-type="fig"}, [2b](#F2){ref-type="fig"}, and [2d](#F2){ref-type="fig"}\]. These results suggested that electromechanical coupling time is a potential index in evaluating cardiac systolic function in SBHF patients.

The Qsb time course was used to detect systolic asynchrony in patients with regional myocardial dysfunction.\[[@ref13]\] In our study, the Qsb, Qst, Rsb, and Rst time course were chosen to evaluate the cardiac systolic function. S wave of TDI represents the beginning of systolic activity of left ventricular, and Q wave on ECG represents the beginning of mechanical activity of left ventricular. Hence, we detected the time course from the Q wave to the beginning of S wave to represent the efficiency that the electrical activity transferred into mechanical activity. As the beginning of S wave was sometimes unclear in TDI, therefore, we supplement the time course of Qst, which is from the Q wave on ECG to the top of S wave on TDI representing the efficiency of electromechanical coupling efficiency. In additional, Rsb and Rst time course were measured to avoid the uncertainty of the Q wave.

Regarding the effects of electromechanical coupling time, the following factors need to be discussed. First, HR is related with the electrical and mechanical activities of the heart.\[[@ref14][@ref15]\] To determine the effects of HR in electromechanical coupling time, the electromechanical coupling time with or without HR correction in SBHF patients and CONs was analyzed in our study. The results showed that the electromechanical coupling durations were all significant longer in SBHF patients than those in CONs with or without HR correction \[[Supplementary Table 1](#T4){ref-type="table"}\], which indicates that HR has no significant influence in the prolongation of electromechanical coupling in the SBHF group.

###### 

Comparison of electromechanical coupling time measurement parameters without HR corrected

  Items      CONs (*n* = 31)   SBHF patients (*n* = 26)   *t*     *P*
  ---------- ----------------- -------------------------- ------- ---------
  Lat-Qsb    67.68 ± 14.55     97.31 ± 29.62^†^           4.652   \<0.001
  Lat-Qst    108.2 ± 13.85     134 ± 41.85\*              3.008   0.005
  Lat-Rsb    40.92 ± 14.01     68.38 ± 29.06^†^           4.401   \<0.001
  Lat-Rst    78.19 ± 13.98     104.6 ± 36.10\*            3.517   0.001
  Pivs-Qsb   66.38 ± 12.68     95.88 ± 25.44^†^           5.38    \<0.001
  Pivs-Qst   106.3 ± 13.25     134.3 ± 32.89^†^           4.337   \<0.001
  Pivs-Rsb   41.83 ± 15.08     65.31 ± 21.40^†^           4.843   \<0.001
  Pivs-Rst   77.23 ± 14.04     99.58 ± 30.54^†^           3.646   \<0.001
  Ant-Qsb    67.6 ± 13.09      93.96 ± 30.09^†^           4.411   \<0.001
  Ant-Qst    106.7 ± 14.19     134.7 ± 46.99\*            3.151   0.003
  Ant-Rsb    41.46 ± 11.95     66.81 ± 27.73^†^           4.337   \<0.001
  Ant-Rst    77.63 ± 14.78     107.4 ± 43.25^†^           3.352   0.002
  Inf-Qsb    69.17 ± 15.78     94.73 ± 24.40^†^           4.596   \<0.001
  Inf-Qst    107.6 ± 20.52     136.7 ± 35.00^†^           3.742   \<0.001
  Inf-Rsb    42.11 ± 15.42     66.08 ± 20.78^†^           4.992   \<0.001
  Inf-Rst    82.38 ± 19.56     106.8 ± 29.61^†^           3.604   \<0.001
  PW-Qsb     67.56 ± 15.56     92.73 ± 24.19^†^           4.572   \<0.001
  PW-Qst     108 ± 19.56       132.6 ± 40.56\*            2.786   0.009
  PW-Rsb     41.59 ± 13.09     64.27 ± 21.13^†^           4.759   \<0.001
  PW-Rst     79.71 ± 14.41     103.7 ± 33.49\*            3.403   0.002
  Aivs-Qsb   69.91 ± 15.42     94.62 ± 25.28^†^           4.351   \<0.001
  Aivs-Qst   104.8 ± 15.73     138 ± 36.46\*              4.323   \<0.001
  Aivs-Rsb   43.07 ± 12.61     64.58 ± 21.1^†^            4.558   \<0.001
  Aivs-Rst   78.19 ± 13.98     104.6 ± 36.10\*            4.155   \<0.001

Data are expressed as mean ± SD. Lat: Lateral wall of left ventricle; Pivs: Posterior ventricular septum of left ventricle; Ant: Anterior wall of left ventricle; Inf: Inferior wall of left ventricle; PW: Posterior wall of left ventricle; Aivs: Anterior ventricular septum of left ventricle; Qsb: from the onset of Q wave on ECG to the beginning of S wave on TDI; Qst: From the onset of Q wave on ECG to the top of S wave on TDI; Rsb: From the top of R wave on ECG to the beginning of S wave on TDI; Rst: From the top of R wave on ECG to the top of S wave on TDI; SD: Standard deviation; CONs: Healthy controls; SBHF: Stage B heart failure; ECG: Electrocardiography; TDI: Tissue Doppler imaging; \**P*\<0.05; ^†^: *P*\<0.01.

Second, the homogeneity of the heart might influence the electromechanical coupling time. In our study, we selected participants with pressure overload-induced heart failure, which is known to lead to homogenous cardiac remodeling.\[[@ref16][@ref17]\] We detected electromechanical coupling time course in six walls of the left ventricle (including Lat, Ant, Inf, PW, Aivs, and Pivs) in SBHF patients and CONs, and the results showed that the indexes of electromechanical coupling time were all significantly longer than those of CONs in six walls of left ventricle \[[Table 3](#T3){ref-type="table"}\]. This suggested that, in pressure overload-induced SBHF, the electromechanical time would not be significantly influenced by the scanning position of TDI.

Third, age affects cardiac function and structure, especially cardiac diastolic function.\[[@ref18][@ref19]\] To determine the influence of age, we compared the electromechanical coupling time in two control groups with significant different ages. The results show that there is no significant difference in electromechanical coupling durations between these two groups \[[Supplementary Table 2](#T5){ref-type="table"}\]. Thus, it suggests that the electromechanical coupling duration is not influenced by age.

###### 

Comparison of electromechanical coupling time measurement in CONs of SBHF patients and CONs of athletes

  Items           CONs of SBHF patients (*n* = 31)   CONs of athletes (*n* = 15)   *t*      *P*
  --------------- ---------------------------------- ----------------------------- -------- ---------
  Age (year)      42.7 ± 13.6                        28.87 ± 4.26                  4.855    \<0.001
  Lat-Qsb (ms)    80.3 ± 14.81                       79.14 ± 16.02                 −0.044   0.965
  Lat-Qst (ms)    129 ± 16.97                        128.8 ± 20.2                  −1.014   0.316
  Lat-Rsb (ms)    48.3 ± 15.18                       52.2 ± 12.73                  0.308    0.759
  Lat-Rst (ms)    93.25 ± 16.72                      98.35 ± 15.09                 −0.873   0.387
  Pivs-Qsb (ms)   80.32 ± 17.35                      82.19 ± 21.78                 −0.303   0.764
  Pivs-Qst (ms)   127.8 ± 20.45                      137 ± 29.67                   −1.21    0.233
  Pivs-Rsb (ms)   48.87 ± 13.7                       49.48 ± 16.31                 −0.132   0.896
  Pivs-Rst (ms)   74.2 ± 11.57                       74.86 ± 10.33                 −0.189   0.851
  Ant-Qsb (ms)    79.37 ± 12.47                      79.64 ± 14.27                 −0.063   0.95
  Ant-Qst (ms)    127 ± 16.13                        132.4 ± 22.39                 −0.911   0.367
  Ant-Rsb (ms)    47.84 ± 12.94                      47.87 ± 12.93                 −0.006   0.995
  Ant-Rst (ms)    92.19 ± 16.13                      95.3 ± 18.2                   −0.575   0.569
  Inf-Qsb (ms)    82.47 ± 17.81                      83.91 ± 26.23                 −0.212   0.833
  Inf-Qst (ms)    127.4 ± 22.58                      136.7 ± 32.31                 −1.068   0.292
  Inf-Rsb (ms)    50.13 ± 16.6                       50.33 ± 16.45                 −0.035   0.972
  Inf-Rst (ms)    97.85 ± 22.51                      108.1 ± 27.27                 −1.262   0.214
  PW-Qsb (ms)     81.89 ± 17.35                      83.01 ± 24.57                 −0.159   0.874
  PW-Qst (ms)     130.3 ± 17.76                      138.3 ± 28.92                 −1.057   0.297
  PW-Rsb (ms)     49.28 ± 14.77                      50.19 ± 12.69                 −0.166   0.869
  PW-Rst (ms)     95.14 ± 17.73                      102.2 ± 23.91                 −1.003   0.322
  Aivs-Qsb (ms)   83.33 ± 17.45                      85.18 ± 24.94                 −0.269   0.79
  Aivs-Qst (ms)   125.1 ± 20.17                      132.3 ± 28.81                 −0.899   0.374
  Aivs-Rsb (ms)   51.13 ± 13.84                      51.51 ± 10.19                 −0.07    0.945
  Aivs-Rst (ms)   93.34 ± 17.84                      96.39 ± 24.43                 −0.587   0.56

Data are expressed as mean ± SD. Lat: Lateral wall of left ventricle; Pivs: Posterior ventricular septum of left ventricle; Ant: Anterior wall of left ventricle; Inf: Inferior wall of left ventricle; PW: Posterior wall of left ventricle; Aivs: Anterior ventricular septum of left ventricle; Qsb: From the onset of Q wave on ECG to the beginning of S wave on TDI; Qst: From the onset of Q wave on ECG to the top of S wave on TDI; Rsb: From the top of R wave on ECG to the beginning of S wave on TDI; Rst: From the top of R wave on ECG to the top of S wave on TDI; SD: Standard deviation; CONs: Healthy controls; SBHF: Stage B heart failure; ECG: Electrocardiography; TDI: Tissue Doppler imaging.

Finally, cardiac hypertrophy can be divided into pathological cardiac hypertrophy and physiological cardiac hypertrophy. To determine whether the electromechanical coupling time is associated with physiological cardiac hypertrophy, we detected the electromechanical coupling time in athletes with exercise-induced hypertrophy,\[[@ref20][@ref21]\] \[Supplementary Tables [3](#T6){ref-type="table"} and [4](#T7){ref-type="table"}\]. The measurement results showed that the athletes\' myocardium was characterized by hypertrophy, but their electromechanical coupling time was not significantly longer than that of CONs \[[Supplementary Table 5](#T8){ref-type="table"}\]. These results showed that the electromechanical coupling time course can be a potential index to distinguish between pathological cardiac hypertrophy and physiological cardiac hypertrophy.

###### 

Comparison of the general characteristics

  Items           CONs (*n* = 15)   Athletes (*n* = 23)   *t*      *P*
  --------------- ----------------- --------------------- -------- ---------
  Age (year)      28.87 ± 4.26      21.09 ± 3.31          −6.318   \<0.001
  BMI (kg/m^2^)   22.07 ± 1.59      21.86 ± 2.37          −0.288   0.775
  HR (bpm)        76.13 ± 10.51     59.09 ± 7.92          −5.698   \<0.001
  SBP (mmHg)      117.14 ± 8.33     111.95 ± 8.89         −1.762   0.087
  DBP (mmHg)      66.29 ± 8.64      69.35 ± 8.02          1.094    0.281

Data are expressed as mean ± SD. BMI: Body mass index; HR: Heart rate; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; SD: Standard deviation; CONs: Healthy controls.

###### 

Comparison of M-mode echocardiographic measurement parameters

  Items         CONs (*n* = 15)   Athletes (*n* = 23)   *t*     *P*
  ------------- ----------------- --------------------- ------- ---------
  IVS (mm)      8.17 ± 0.94       9.41 ± 1.23           3.323   0.002
  LVPW;d (mm)   8.10 ± 0.76       9.44 ± 1.27           4.076   \<0.001
  LVEDD (ml)    49.56 ± 3.44      54.54 ± 3.51          4.314   \<0.001
  LVESD (ml)    31.09 ± 0.15      34.46 ± 3.11          3.199   0.003
  RWT           0.33 ± 0.33       0.35 ± 0.49           1.360   0.182
  LVMI          83.51 ± 14.88     109.06 ± 20.48        4.161   \<0.001
  LVEF (%)      60.33 ± 5.21      65.39 ± 4.21          3.298   0.002
  E/A           1.60 ± 0.34       2.11 ± 0.13           2.912   0.006
  E/Em          0.05 ± 0.01       0.05 ± 0.01           0.451   0.655

Data are expressed as mean ± SD. IVS: Inter-ventricular septum; LVPW;d: Left ventricular posterior wall; LVEDD: Left ventricular end-diastolic dimension; LVESD: Left ventricular end-systolic dimension; RWT: Relative wall thickness; LVMI: Left ventricular mass index; LVEF: Left ventricular ejection fraction; SD: Standard deviation; CONs: Healthy controls.

###### 

Comparison of electromechanical coupling time measurement parameters

  Items      CONs (*n* = 15)   Athletes (*n* = 23)   *t*      *P*
  ---------- ----------------- --------------------- -------- ---------
  Lat-Qsb    80.52 ± 18.65     79.41 ± 16.02         −0.197   0.845
  Lat-Qst    135.62 ± 26.91    128.80 ± 20.20        −0.893   0.378
  Lat-Rsb    46.83 ± 16.44     52.2 ± 12.73          1.136    0.264
  Lat-Rst    98.58 ± 23.56     98.35 ± 15.09         −0.012   0.991
  Pivs-Qsb   82.02 ± 22.67     82.46 ± 14.93         0.047    0.962
  Pivs-Qst   137.76 ± 30.70    130.98 ± 20.3         −0.685   0.498
  Pivs-Rsb   49.48 ± 16.31     56.29 ± 9.48          1.390    0.180
  Pivs-Rst   75.43 ± 10.47     58.1 ± 7.78           −5.698   \<0.001
  Ant-Qsb    80.27 ± 14.65     81.96 ± 16.81         0.420    0.677
  Ant-Qst    133.81 ± 22.60    130.19 ± 21.63        −0.283   0.779
  Ant-Rsb    47.71 ± 13.45     55.35 ± 12.74         1.674    0.104
  Ant-Rst    96.52 ± 18.33     99.15 ± 16.25         0.647    0.522
  Inf-Qsb    83.91 ± 27.39     84.82 ± 16.37         0.123    0.903
  Inf-Qst    136.55 ± 33.88    123.36 ± 35.11        −1.082   0.290
  Inf-Rsb    50.37 ± 17.25     54.37 ± 11.37         0.810    0.424
  Inf-Rst    107.62 ± 28.55    97.05 ± 16.27         −1.418   0.167
  PW-Qsb     82.91 ± 26.05     83.42 ± 15.9          0.055    0.956
  PW-Qst     140.21 ± 30.01    128.74 ± 28.48        −0.864   0.395
  PW-Rsb     46.51 ± 16.88     57.08 ± 10.57         1.529    0.138
  PW-Rst     104.22 ± 24.42    99.35 ± 16.12         −0.387   0.701
  Aivs-Qsb   84.86 ± 26.27     83.68 ± 19.79         −0.184   0.855
  Aivs-Qst   133.38 ± 30.12    134.94 ± 22.92        0.283    0.779
  Aivs-Rsb   51.19 ± 19.26     56.06 ± 14.62         0.742    0.464
  Aivs-Rst   97.19 ± 25.60     104.32 ± 19.74        1.618    0.116

Data are expressed as mean ± SD. Lat: Lateral wall of left ventricle; Pivs: Posterior ventricular septum of left ventricle; Ant: Anterior wall of left ventricle; Inf: Inferior wall of left ventricle; PW: Posterior wall of left ventricle; Aivs: Anterior ventricular septum of left ventricle; Qsb: From the onset of Q wave on ECG to the beginning of S wave on TDI; Qst: From the onset of Q wave on ECG to the top of S wave on TDI; Rsb: From the top of R wave on ECG to the beginning of S wave on TDI; Rst: From the top of R wave on ECG to the top of S wave on TDI; SD: Standard deviation; CONs: Healthy controls; ECG: Electrocardiography; TDI: Tissue Doppler imaging.

E/A and E/Em were most used index in evaluating cardiac diastolic function. Aging and hypertension are remarkably related cardiac diastolic function, and cardiac diastolic dysfunction often occurs first in hypertension-induced cardiac hypertrophy.\[[@ref22]\] In our study, cardiac diastolic function was significantly decreased in SBHF patients compared with CONs. This is reasonable, for the SBHF patients with remarkable cardiac hypertrophy. For the LVEF in SBHF patients was not significantly decreased, a more sensitive index for evaluating cardiac systolic function is urgently needed. The electromechanical coupling time course in our study related with the systolic mechanical activity of the heart, and our results showed that electromechanical coupling time course was significantly longer than CONs. In addition, the sensitivity and specificity of electromechanical coupling time are better than LVEF. These results showed that the electromechanical coupling time in our study was a potential index to evaluate cardiac systolic function but not the diastolic function.

However, there are still some limitations in our study. One limitation is the lack of follow-up study in humans. Moreover, the sample size is not big enough, and different types of heart failure need to be studied in the future.

In conclusion, SBHF patients have already prolonged electromechanical coupling time but with normal LVEF compared with CONs. Our study provides a potential index for evaluating cardiac systolic function in heart failure at a much earlier stage of heart failure.

*Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website*.
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Click here for additional data file.
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